Finanzwire Finanzwire
Basculer en Français
11104 Companies
244274 Keywords
172370 Articles
131639 Press releases
Headlines Articles Press releases Secarna Pharmaceuticals GmbH & Co. KG Remove
  1. Home
  2. Companies
  3. Secarna Pharmaceuticals GmbH & Co. KG
Finanzwire
Basculer en Français
Headlines Articles Press releases

News

  • PRESS RELEASE

    published on 11/03/2023 at 18:05, 2 years 10 months ago

    Secarna Pharmaceuticals presents data at SITC demonstrating the potential of antisense oligonucleotides in targeting NRP1

    Logo of Secarna Pharmaceuticals GmbH & Co. KG
  • PRESS RELEASE

    published on 10/25/2023 at 15:00, 2 years 11 months ago

    Secarna Pharmaceuticals presents data at OTS showcasing unique characteristics and factors with a role in the activity and side effect profile of LNA-modified ASOs

    Logo of Secarna Pharmaceuticals GmbH & Co. KG
  • PRESS RELEASE

    published on 10/17/2023 at 14:00, 2 years 11 months ago

    Secarna Pharmaceuticals to present two posters showcasing the innovation potential of the LNAplus platform at the 19th Annual Meeting of the Oligonucleotide Therapeutic Society

    Logo of Secarna Pharmaceuticals GmbH & Co. KG
  • PRESS RELEASE

    published on 07/06/2023 at 14:00, 3 years 2 months ago

    Secarna Pharmaceuticals publishes new preclinical data in The Journal of Immunology demonstrating potent therapeutic activity of LNAplus™ ASO targeting NLRP3 in debilitating autoinflammatory diseases

    Logo of Secarna Pharmaceuticals GmbH & Co. KG
  • PRESS RELEASE

    published on 06/05/2023 at 14:00, 3 years 3 months ago

    Secarna Pharmaceuticals announces publication of new preclinical data showing durable antitumor activity of LNAplus™-based ASOs that both stimulate the innate immune system and suppress PD-L1 expressi

    Logo of Secarna Pharmaceuticals GmbH & Co. KG
  • PRESS RELEASE

    published on 03/27/2023 at 16:04, 3 years 6 months ago

    Secarna Pharmaceuticals and SciNeuro Pharmaceuticals enter into research and option agreement in the field of CNS diseases

    Logo of Secarna Pharmaceuticals GmbH & Co. KG
Previous page
1 ... 3 4
Accesswire
  • Published on 10/01/2026 at 01:21, 5 hours 43 minutes ago

    Revival Gold Announces Filing of Final Base Shelf Prospectus

  • Published on 10/01/2026 at 01:00, 6 hours 4 minutes ago

    Algo Grande Copper Secures Five-Year Surface Access Agreement With Ejido Palos Chinos at the Adelita Project

  • Published on 09/30/2026 at 23:30, 7 hours 34 minutes ago

    Early Warning News Release Issued with Respect to the Acquisition of Securities of Cypher Metaverse Inc.

  • Published on 09/30/2026 at 20:35, 10 hours 29 minutes ago

    Fairplay Ventures Inc. Enters Into Definitive Agreement to Complete Qualifying Transaction With Ampere Metals Pty. Limited

  • Published on 09/30/2026 at 15:50, 15 hours 14 minutes ago

    Innodata Opens Motion-Capture AI Lab to Help Humanoids Move Like Humans

View all ACCESSWIRE
EQS Group
  • Published on 10/01/2026 at 05:05, 1 hour 59 minutes ago

    Emerald Clinical Trials Appoints Michael Stibilj as Chief Executive Officer to Lead Next Phase of Global Growth

  • Published on 09/30/2026 at 23:23, 7 hours 41 minutes ago

    LM PAY S.A. publishes audited FY 2025 results: EBIT reaches PLN 12.4 million and exceeds preliminary result and guidance

  • Published on 09/30/2026 at 22:34, 8 hours 30 minutes ago

    The Change of Date of the Annual Report 2025 Publication

  • Published on 09/30/2026 at 22:05, 8 hours 59 minutes ago

    ADS-TEC Energy Reports First Half 2026 Results; Advances Gigawatt-Scale SKM Storage Project and Strengthens its Position to Scale Own & Operate Model

  • Published on 09/30/2026 at 22:05, 8 hours 59 minutes ago

    Abivax to Present Data on Obefazimod at United European Gastroenterology (UEG) Week 2026

View all EQS
Les Echos
  • Published on 09/30/2026 at 18:44, 12 hours 19 minutes ago

    Broadcast of the 5th edition of “On the way up”

  • Published on 09/30/2026 at 18:15, 12 hours 49 minutes ago

    The Belgian State and ENGIE Group have agreed to extend the target date for concluding the Heads of Terms until 4 november 2026

  • Published on 09/30/2026 at 18:00, 13 hours 4 minutes ago

    Thales announces the distribution of an interim dividend

  • Published on 09/30/2026 at 18:00, 13 hours 4 minutes ago

    Cie du Bois Sauvage : Compagnie du Bois Sauvage increases its stake in Eaglestone to support its long-term development (Inside information)

  • Published on 09/30/2026 at 12:00, 19 hours 4 minutes ago

    Capital increase through exercise of subscription rights

View all LES ECHOS COMFI WIRE

With finanzwire.com, you can follow all the latest financial news in real time from the best sources for companies listed on the Paris, Brussels, Amsterdam, Lisbon, Frankfurt and New York stock exchanges. You'll have access to summary articles written by us and press releases published by the companies themselves.

Finanzwire

87, rue Ordener - 75018 Paris

Contact us

+33 1 42 23 83 61

© 2026 Finanzwire

Contact Authors Cookies policy Terms and conditions Privacy policy